Literature DB >> 30714285

Evaluation of the accuracy of multiparametric MRI for predicting prostate cancer pathology and tumour staging in the real world: an multicentre study.

Jonathan Kam1,2, Yuigi Yuminaga1, Matthew Krelle3, Dominic Gavin3, Samantha Koschel4, Kushlan Aluwihare5, Tom Sutherland3, Sarah Skinner4, Janelle Brennan3,4, Lih-Ming Wong3,6, Mark Louie-Johnsun1,2.   

Abstract

OBJECTIVES: To assess the accuracy of multiparametric magnetic resonance imaging (mpMRI) for the detection of significant prostate cancer in men undergoing radical prostatectomy (RP) in an Australian multicentre setting, and to assess concordance between mpMRI and RP for local tumour staging and index lesion locations. PATIENTS AND METHODS: Men who underwent mpMRI within 12 months of RP between January 2013 and August 2016 at three Australian sites were included (Central Coast, NSW, St Vincents Hospital, Melbourne, Vic., and Bendigo Hospital, Vic.). The results of mpMRI were compared with the final RP specimen to analyse the performance of mpMRI for significant prostate cancer detection, index lesion localization, prediction of T3 disease and lymph node metastasis. A comparison between mpMRI cases performed using the technical and reporting specifications of Prostate Imaging Reporting and Data System (PI-RADS) version 1 and version 2 was also performed. Data analysis was performed using spss 24.0.
RESULTS: A total of 235 cases were included for analysis. mpMRI PI-RADS score ≥3 had a 91% sensitivity and 95% positive predictive value (PPV) for significant prostate cancer at RP. The overall concordance between index lesion location on mpMRI and RP specimen was 75%. The sensitivity for predication of significant prostate cancer was higher in the PI-RADS version 2 cases compared with PI-RADS version 1 (87-99%; P = 0.005). Index lesion concordance was higher in the PI-RADS version 2 group (68% vs 91%; P = 0.002). mpMRI had a 38% sensitivity, 95% specificity, 90% PPV and 57% negative predictive value for extraprostatic disease. Sensitivity for prediction of T3 disease improved from 30% to 62% (P = 0.008) with PI-RADS version 2.
CONCLUSIONS: In patients undergoing RP, an abnormal mpMRI is highly predictive (95% PPV) of significant prostate cancer, with an index lesion concordance of 75%. There has been a significant improvement in accuracy after the adoption of PI-RADS version 2 technical specifications and reporting criteria; however; further study is required to determine if this is attributable to improved experience with mpMRI or changes in the PI-RADS system.
© 2019 The Authors BJU International © 2019 BJU International Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  #PCSM; #ProstateCancer; multiparametric MRI; radical prostatectomy

Mesh:

Year:  2019        PMID: 30714285     DOI: 10.1111/bju.14696

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  5 in total

1.  Use of high-resolution micro-ultrasound to predict extraprostatic extension of prostate cancer prior to surgery: a prospective single-institutional study.

Authors:  Vittorio Fasulo; Nicolò Maria Buffi; Federica Regis; Marco Paciotti; Fancesco Persico; Davide Maffei; Alessandro Uleri; Alberto Saita; Paolo Casale; Rodolfo Hurle; Massimo Lazzeri; Giorgio Guazzoni; Giovanni Lughezzani
Journal:  World J Urol       Date:  2022-01-10       Impact factor: 4.226

Review 2.  More than Meets the Eye: Using Textural Analysis and Artificial Intelligence as Decision Support Tools in Prostate Cancer Diagnosis-A Systematic Review.

Authors:  Teodora Telecan; Iulia Andras; Nicolae Crisan; Lorin Giurgiu; Emanuel Darius Căta; Cosmin Caraiani; Andrei Lebovici; Bianca Boca; Zoltan Balint; Laura Diosan; Monica Lupsor-Platon
Journal:  J Pers Med       Date:  2022-06-16

3.  Prostate cancer in PI-RADS scores 1 and 2 version 2.1: a comparison to previous PI-RADS versions.

Authors:  Katja Bogner; Karl Engelhard; Wolfgang Wuest; Sajad Hamel
Journal:  Abdom Radiol (NY)       Date:  2022-03-21

4.  The diagnostic accuracy of multiparametric MRI for detection and localization of prostate cancer depends on the affected region.

Authors:  Martina Martins; Stefano Regusci; Stephane Rohner; Ildiko Szalay-Quinodoz; Georges-Antoine De Boccard; Louise Strom; Gerjon Hannink; Sonia Ramos-Pascual; Charles Henry Rochat
Journal:  BJUI Compass       Date:  2020-11-28

5.  The impact of health-policy-driven subsidisation of prostate magnetic resonance imaging on transperineal prostate biopsy practice and outcomes.

Authors:  Gavin Wei; Fairleigh Reeves; Marlon Perera; Brian D Kelly; Stephen Esler; Damien Bolton; Greg Jack
Journal:  BJUI Compass       Date:  2022-02-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.